Tim Edwards becomes chairman of BIA in UK

Chief executive of Cellzome succeeds Dr Clive Dix

The BioIndustry Association (BIA) board has elected Tim Edwards as its new chairman. He succeeds Dr Clive Dix, who steps down following two-and-a-half years as chairman, but will remain a member of the BIA board.

Edwards is chief executive of drug discovery company Cellzome and previously held various positions at British Biotech.

‘I eagerly look forward to helping the BIA build on the successes it has achieved to date. The UK life sciences sector continues to face a number of challenges which the BIA can help its members address and overcome,’ he said.

You may also like

Research & Development

The power of national collaboration

To expedite the scale-up and production of a COVID-19 vaccine, the UK BioIndustry Association issued a call to arms to its members, reports Steve Bates, CEO
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Media

New report reveals UK has strongest R&D pipeline in Europe

A new report — Pipeline Progressing — released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals the UK has the strongest clinical and preclinical pipeline in Europe
Media

Life Science Industry Coalition position paper released

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
Media

Safeguarding public health must be number one priority

To coincide with the House of Commons Health Select Committee on <i>Brexit: the regulation of medicines, medical devices and substances of human origin</i>, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit
Media

BIA responds to Brexit negotiation announcement

BIA reacts to announcement from European Commission President Jean-Claude Juncker and Prime Minister Theresa May that ‘sufficient progress’ has been agreed on phase one of the Brexit negotiations
Subscribe now